Search for a trial

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
EVALUATING THE EFFICACY AND SAFETY OF A HUMAN MONOCLONAL
ANTIBODY, REGN2222, FOR THE PREVENTION OF MEDICALLY ATTENDED
RSV INFECTION IN PRETERM INFANTS

Primary ObjectivesPart A:To determine the pharmacokinetics (PK) of intramuscular (IM)administrations of REGN2222Part B:To demonstrate the efficacy of REGN2222 in preventing medicallyattended respiratory syncytial virus (RSV) infections (subjects…